Presentation is loading. Please wait.

Presentation is loading. Please wait.

Parameswaran N. Hari, Navneet S

Published byよしたか ことじ Modified over 5 years ago

Similar presentations

Presentation on theme: "Parameswaran N. Hari, Navneet S"— Presentation transcript:

1 Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 
Parameswaran N. Hari, Navneet S. Majhail, Mei-Jie Zhang, Anna Hassebroek, Fareeha Siddiqui, Karen Ballen, Asad Bashey, Jenny Bird, Cesar O. Freytes, John Gibson, Gregaory Hale, Leona Holmberg, Ram Kamble, Robert A. Kyle, Hillard M. Lazarus, Charles F. LeMaistre, Fausto Loberiza, Angelo Maiolino, Philip L. McCarthy, Gustavo Milone, Nancy Omondi, Donna E. Reece, Matthew Seftel, Michael Trigg, David Vesole, Brendan Weiss, Peter Wiernik, Stephanie J. Lee, J. Douglas Rizzo, Paulette Mehta  Biology of Blood and Marrow Transplantation  Volume 16, Issue 3, Pages (March 2010) DOI: /j.bbmt Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence of nonrelapse mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Cumulative incidence of disease relapse and progression.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Probability of progression-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Probability of overall survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Parameswaran N. Hari, Navneet S"

Similar presentations

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 

Similar presentations

Ads by Google